Method for prediction of risk of developing rachitism in infants suffering thyroid insufficiency |
|
|
IPC classes for russian patent Method for prediction of risk of developing rachitism in infants suffering thyroid insufficiency (RU 2560847):
|
FIELD: medicine. SUBSTANCE: method involves biochemical serum test to measure parathyroid hormone (PTH), calcitonin (CT) and vitamin D (25OHD3), thyreotropic hormone (TTH) and thyroid hormone (free T4) in newborns with the test to be repeated 3 months later. If the minimum thyroid insufficiency tends to persist (high TTG concentration more than 3.4 mcIU/ml and/or lowered free T4 below 10 pmole/ml), whereas PHT grows by 25-30%, CT decreases by 15-20%, 25OHD3 decreases by 40-50% in relation to the initial values, a risk of rachitism is stated that enables performing early pre-clinical diagnosis of the disease. The presented method enables considering the hormonal reaction of calcium-regulating and hypophyseal-thyreoid systems, performing the pre-clinical diagnosis of rachitism, predicting a risk, a clinical course, a severity of the disease, determining the necessary volume of an adequate therapy (dosage) timely and the length thereof in the infants suffering rachitism accompanied by thyroid insufficiency. Using the presented method enables detecting the group of outpatient children pertaining to the prophylaxis for the purpose of performing timely therapeutic actions aiming at reducing a risk of rachitism and bone pathologies. EFFECT: method is easy to use and interpret the results, can be used by a wide range of general paediatricians, provides monitoring the quality of the therapeutic actions performed. 2 ex
|
Method for prediction of ovulatory menstrual cycles in females with oligomenorrhea in past medical history / 2549985
Blood serum anti-Mullerian hormone (AMH) is measured on the 3-5th day of the menstrual cycle by the immunoenzyme method, and an antral follicle count of 2-5 mm in diameter is derived on the 5-7th day of the menstrual cycle by means of transvaginal ultrasonic examination. The ovulatory menstrual cycles are predicted, if the measured AMH is from 5.0 to 8.0 ng/ml, while the antral follicle count in the ovary makes up to 10.
Method for assessing ovarian aromatase activity / 2549491
Serum hormones are measured on the second day of the menstrual cycle prior to peroral administering letrozole aromatase inhibitor 10 mg and 48 hours after; pre-letrozole oestradiol and anti-Mullerian hormone and post-letrozole oestradiol are measured. An absolute decrease of post-letrozole oestradiol is determined, and an ovarian aromatase activity coefficient (K) is determined by formula. If K <9.1, the low ovarian aromatase activity is determined, the 9.1<K<27.3 shows the normal activity, while K>27.3 - the high activity.
Method for selecting trained workers maintaining railroad tunnel into risk group of incipient signs of health situations / 2546929
Method involves measuring total blood thyroxin, conducting spinal X-ray osteodensitometry and spirometry, and measuring mineral bone density at the lumbar level of L2-L3, and maximal expiratory flow at 25% and 50% of respiratory function. The obtained data are used to calculate F by formula F=25.1-0.14×a1-15.7×a2+0.42×a3-0.034×a4, wherein 25.1 is a constant; 0.14; 15.7; 0.42; 0.034 are discriminant coefficients; a1, 2,…, 4 are numerical values of the conducted examination; a1 is the total thyroxin concentration, nmol/l; a2 is a bone L2-L3 density coefficient; a3 is the maximal expiratory flow at 25% according to respiratory function, %; a4 is the maximal expiratory flow at 50% according to respiratory function, %. If F is equal to or more than the constant, the patient is stated to have no signs of health situations specific for this type of industry; if F is less than the constant, the patient is referred to a risk group of health situations.
Method for detecting synchronous tumour growth in male patients suffering colon cancer / 2546033
Invention refers to medicine, namely to a method for detecting the synchronous tumour growth in the male patients suffering colon cancer. Substance of the invention consists in measuring preoperative blood testosterone and intestinal cell-stimulating hormone by Immunotech test systems (Czech Republic) in the male patients suffering colon cancer. Testosterone/intestinal cell-stimulating hormone ratio is calculated; if the derived value falls within the range of 0.45-2.18 enables stating the presence of single colon cancer, while the values within the range of 0.03-0.38 provides stating the presence of synchronous tumours.
Diagnostic technique for adolescent's reproductive disorders accompanying chronic renal pathology / 2536288
Technique involves a blood serum examination for thyrotropic hormone, mcUnit/ml, free T4, pmole/l, prolactine, mIU/ml, follicle-stimulating hormone, mIU/ml, lutenizing hormone, mIU/ml, testosterone, nmole/l, dehydroepiandrosterone sulphate, mcg/ml, cortisol, nmole/l, oestradiol, pg/ml, 17-OH progesterone, nmole/l. Calculating an integral hormone state (HIS) by formula follows. If the HIS value is below 0.799, a habitual disorder is stated, which is accompanied by a minimum risk of the reproductive disorders. The HIS values falling from the range of 0.800 to 1.000 provides stating the tensed hormonal regulation reflecting a moderate risk of the reproductive disorders. The disturbed interhormonal cooperation corresponds to the HIS value falling within the range of 1.001 to ≤1.210 that represents a high risk of the reproductive disorders. The HIS value of more than 1.211 shows the lack of reserves that testifies to a very high risk of the reproductive disorders.
Method of diagnostics of menstrual dysfunction against background of polycystic ovarian syndrome by immature girls / 2535096
For immature girls after day 3-5 of menstrual cycle a level of Anti-Mullerian Hormone is determined in blood serum by method of enzyme multiplied immunoassay (ELISA), and if its value exceeds 5.2 ng/ml the menstrual dysfunction is diagnosed against the background of polycystic ovarian syndrome.
Method for early prevention of gestational complications / 2530624
Method involves detecting a threatening miscarriage and a carrier state of the polymorphism in the gene of folate metabolism, as well as a CD54+ lymphocyte ratio, lactoferrin and β-subunit of human chorionic gonadotropin (β-HCG) levels in venous blood of a pregnant woman from the onset of pregnancy to the end of the first trimester. That is followed by calculating a prognostic index (PI) by formula: PI=0.7199X1+1.2552X2-0.00653X3-0.0009X4+0.0722X5+1.1277, wherein X1 is the threatening miscarriage, yes/no (1/0); X2 is the polymorphism in the gene of folate metabolism, yes/no (1/0); X3 is the CD54+ lymphocyte ratio, %; X4 is the lactoferrin level, ng/ml; X5 is the concentration of the free β-subunit of human chorionic gonadotropin (β-HCG), ng/ml. If PI<0, the gestational complications are predicted, while PI>0 enables stating a low risk of pathological conditions accompanying pregnancy. A sensitivity of the presented method makes 81.2%, its specificity is 85.1%. The method effectiveness is 83.2%.
Diagnostic technique for renal functional reserve / 2528903
Invention refers to medicine. Substance of the early diagnostic technique for chronic renal disease consists in using a dosage range of dopamine of 1 to 3 mcg/kg of body weight and a standard water load of 200 ml. No glomerular filtration rate increase testifies to the presence of early signs of chronic renal disease.
Diagnostic technique for clinically latent hypercorticoidism in patients suffering from stype 2 diabetes mellitus or obesity / 2521387
First stage comprises a night suppressive test with dexamethasone 1 mg with a test considered to be positive, if plasma cortisol measured at 8.00 in the next morning exceeds 50 nmole/l. If the first stage has a positive result, the second stage is performed 1-2 days later. At the second stage, blood plasma cortisol at 24.00, daily urine free cortisol, a coefficient of circadian rhythm of cortisol secretion are determined on the same day. If at least two of the three test results are above normal: plasma cortisol at 24.00 is more than 207 nmole/l, daily urine free cortisol is more than 180 mcg/day, coefficient of circadian rhythm of cortisol secretion is more than 50%, hypercorticoidism syndrome is diagnosed. The presented technique provides higher accuracy and simplifies diagnosing of the given disease.
Solid phase enzyme-immunoassay (eliza) for vascular endothelial growth factor (vegf) / 2517301
Invention relates to the field of immunology, namely to enzyme-immunoassay, in particular to a method of detecting forms of vascular endothelial growth factor (VEGF) with a size more than 110 amino acids in a biological sample. The method includes the following stages: contact and incubation of the biological sample with an uptake reagent, immobilised on a solid substrate, where the uptake reagent contains a monoclonal antibody, which recognises and specifically binds with residues, in quantity more than 110, from human VEGF; separation of the biological sample from the immobilised uptake reagents; contact of the immobilised molecular complex of the reagent of the uptake-target with detected antibody, which binds with VEGF domains, responsible for binding with KDR and/or FLT1 receptor, or which binds with an epitope in VEGF1-110; measurement of the level of VEGF110+, bound with reagents of the uptake, with application of means of detection for the detected antibody. Set of immune assay reagents for detection of VEGF110+ forms in the biological sample. An antibody 5C3, obtained from hybridoma 5C3.1.1 with a depositary number PTA-7737, with the said antibody 5C3 binding VEGF110+ forms, including VEGF121+. Hybridoma 5C3.1.1, deposited in ATCC with the depositary number PTA-7737, to obtain the monoclonal antibody 5C3.
Method for differential diagnostics of mammary diseases in men / 2244308
The present innovation deals with biochemical trials: before the onset of therapy in men one should detect blood content of thyroid hormone - free thyroxine - and at its level being 10.3-12.9 pmol/l one should diagnose mammary cancer, at the level of free throxine being 18.7-31.0 pmol/l - one should predict gynecomastia. The method enables to detect the direction of pathological process and carry out due correction of therapy tactics in men with either gynecomastia or mammary cancer.
Method for predicting the delay of intrauterine fetal development / 2246733
The method deals with studying blood serum of pregnant woman to detect the content of insulin-like growth factor (IGF) and vascular-endothelial growth factor (VEGF) and calculate the coefficient of their ratio: at its value being equal to 28.5 and lower it is possible to diagnose the delay of fetal development.
Method for differential diagnostic of chronic hepatitis and hepatic cirrhosis / 2254577
Thyroglobulin content is determined in blood serum using enzyme immunoassay. When thyroglobulin level is increased by 2 times and more compared in contrast with normal one chronic hepatitis is diagnosed, and when thyroglobulin level is decreased by 1.5-2.5 times in contrast with normal one hepatic cirrhosis is diagnosed.
Method for evaluating combined schizophrenia treatment based on atypical antipsychotic drugs and rations and electroconvulsive shock therapy / 2256181
Method involves determining dehydroepiandrosterone sulfate concentration in blood serum. Its growth above 30% when compared to the initial one being observed, treatment efficiency is determined as negative.
Method for diagnosing obliterated forms of congenital suprarenal gland cortex hyperplasia / 2261447
Method involves applying high effectiveness liquid chromatography for determining cortisol, cortisone 11-deoxycorticosterone, 11-deoxycortisone concentration in blood and free cortisol and free cortisone excretion with urine. Ratios of F/E and FF/FE are calculated, where F is the cortisol level in blood; E is the cortisone level in blood; FF is the free cortisol excretion with urine and FE is the free cortisone excretion with urine. The cortisol level in blood not exceeding norm and at least two of three signs: F/E ratio reduction by 25% and more, FF/FE ratio reduction by 25% and more, free cortisol excretion with urine being equal to 25% and more, obliterated forms of congenital suprarenal gland cortex hyperplasia is diagnosed. Corticosterone level in blood growing by 50% and higher, 21-hydroxylase defect is considered to be the case. 11-deoxycorticosterone and/or 11-deoxycortisone concentration in blood being et or greater than 50%, 11β-hydroxylase defect is considered to be the case.
Method for diagnosing atrophic gastritis cases / 2262706
Method involves making pepsinogen 1, gastrin and Helicopter pylori infection marker combinations analysis and making input of the obtained results into data processing means comprising operation system, means for receiving, transmitting and processing data. The mentioned data processing means is usable for comparing the measured concentration value of a substance under study to a threshold value associated to the substance under study and producing information as a response to comparison results and additionally to other entered data. A set and software are used for implementing the method.
Method for predicting relapse of mammary cancer / 2263319
In the course of surveying in menopausal women after complex therapy one should state the development of mammary cancer at decreased ratio of estriol concentration to the sum of estrone and estradiol urinary concentrations from 1.68±0.23 in relapse-free patients up to 0.74±0.12 - in patients living without relapses for less than a year, up to 0.65±0.13 in patients living without relapse from 2 up to 6 years and up to 0.50±0.10 in patients with relapse-free period from 6 to 10 years. The innovation provides pre-clinical detection of mammary cancer relapse.
Method for predicting fetoplacental insufficiency in pregnant women with thyroid diseases / 2263919
Except detecting placental lactogen in blood serum one should study the content of alphafetoprotein. At placental lactogen content being below 75% against the norm and content of alphafetoprotein below 70% against the norm it is possible to conclude upon availability of fetoplacental insufficiency.
Method for predicting cholecystitis and cholelithiasis / 2263920
While diagnosing cholecystitis and cholelithiasis due to ultrasound testing one should additionally study blood plasma and bile to detect there the content of prostaglandins PGE2 and PGF2α. At PGE2/PGF2α ratio in blood plasma being equal to 6 and more, and, also, at decreased level of biliary cholecystokinin-pancreosimin by 38% and more, biliary PGE2 by 59% and more and increased level of biliary prostaglandin PGF2α by 5.9 times and more against the norm one should diagnose chlecystitis and cholelithiasis. The innovation enables to detect the above-mentioned diseases at earlier stage.
Method for predicting powerless labor in pregnant nodular goiter surgically treated on goiter occasion during pregnancy under medical supervision / 2273456
Method involves determining thyroid gland node diameter and thyrotropic hormone by applying ultrasonic examination approach. Histological examination is carried out with conclusion concerning morphologic nature being obtained like nodular colloid proliferating goiter or thyroid gland adenoma. Diagnostic index Σ is calculated from formula Σ=0.49*K1+0.07*K2-0.5*K3+1.76*K4-1.53, where K1 is the thyroid gland node diameter; K2 is the TTH concentration; K3 is the nodular colloid proliferating goiter index equal to 1 or 0; K4 is the thyroid gland adenoma index equal to 1 or 0. Diagnostic index Σ being less than zero, conclusions concerning powerless labor threat is to be drawn.